Prestige Biopharma Seeks Collaboration Opportunities at BIO USA

Pursuing Partnerships in Antibody Drugs and Biosimilars

Prestige Biopharma announced on the 16th that it will participate in "BIO USA 2026," which will be held in San Diego, USA from June 22 to 25 (local time), to expand business development with global pharmaceutical and biotechnology companies.

At this event, the company plans to accelerate its two-track strategy, focusing on global antibody drug partnering and expanding biosimilar commercialization. In the antibody drug segment, Prestige Biopharma will initiate joint development and technology transfer discussions for PBP1510 and PBP1710. In the biosimilar segment, the focus will be on advancing the North American entry and global commercialization of the Avastin biosimilar "HD204" (brand name: Vasforada), and on selecting a North American partner for the Herceptin biosimilar "HD201" (brand name: Tuzneu).

Prestige Biopharma Group plans to discuss joint development and commercialization strategies for its follow-up pipeline with global pharmaceutical and biotechnology companies, based on its integrated value chain that connects development, production, and commercialization. The company will also showcase its technology for subcutaneous (SC) formulation conversion of antibody medicines, as well as its AI-based research and development and biomanufacturing capabilities.

In addition, Prestige Biopharma will share its AI application capabilities in drug target discovery, antibody optimization, bioprocessing, and quality prediction, as well as the current status of next-generation antibody delivery platform research and development. The company will also explore collaboration opportunities with related companies.

This content was produced with the assistance of AI translation services.